Loading resource…

SepNet Critical Care Trials Group
The study involved 440 adults with septic shock treated with albumin or standard fluid therapy across 23 intensive care units in Germany. The trial aimed to determine if albumin supplementation could reduce mortality rates in this patient population. Despite the hypothesis, the study found no significant difference in 90-day mortality between the albumin group and the control group. The trial was terminated prematurely due to low enrollment rates.
No account needed